Log In
Print
BCIQ
Print
Print this Print this
 

AGT-182

  Manage Alerts
Collapse Summary General Information
Company ArmaGen Technologies Inc.
DescriptionIduronate-2-sulfatase (IDS) using Trojan horse technology
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis II (MPS II, Hunter syndrome)
Regulatory Designation

U.S. - Orphan Drug (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome));
EU - Orphan Drug (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome))

Partner

Shire plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today